Skip to main
GOSS

GOSS Stock Forecast & Price Target

GOSS Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 29%
Hold 29%
Sell 14%
Strong Sell 0%

Bulls say

Gossamer Bio is a clinical-stage biopharmaceutical company with a positive outlook due to its expanding pipeline of promising products addressing unmet needs in immunology, inflammation, and oncology, as well as recent financial actions aimed at reducing debt and extending maturity. With a strong clinical framework and management's confidence in data durability and safety, analysts anticipate positive results for seralutinib in pulmonary arterial hypertension, contributing to a projected price target of $10 per share.

Bears say

Gossamer Bio is facing several challenges that could significantly impact its future prospects. These include potential delays in obtaining regulatory approval for its pipeline products, specifically Seralutinib, due to potential requirements for additional data or longer studies. The company is also facing financial struggles, as evidenced by its recent exchange offer to address its convertible debt due in 2027 and its need for additional financing to support commercial launch. Furthermore, their flagship product, Seralutinib, may have limited addressable market opportunities, and its current data may not meet investor expectations. These factors lead to a negative outlook on Gossamer Bio's stock, with a significant decrease in its target price to $1/share and a downgrade to a Neutral rating.

GOSS has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 29% recommend Buy, 29% suggest Holding, 14% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Gossamer Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Gossamer Bio Inc (GOSS) Forecast

Analysts have given GOSS a Buy based on their latest research and market trends.

According to 7 analysts, GOSS has a Buy consensus rating as of Jun 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Gossamer Bio Inc (GOSS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.